NOV-205

Cellectar Biosciences, Inc. · Phase 2 active Small molecule

At a glance

Generic name	NOV-205
Sponsor	Cellectar Biosciences, Inc.
Modality	Small molecule
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A Trial of NOV-205 in Hepatitis C Patients Who Failed Standard Therapy (PHASE2)
Safety and PK Study of NOV-205 to Treat Chronic HCV Who Fail Standard Therapy (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

NOV-205 CI brief — competitive landscape report
NOV-205 updates RSS · CI watch RSS
Cellectar Biosciences, Inc. portfolio CI